Evolocumab

Evolocumab (INN, trade name Repatha) is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).

PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.